These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 39179585)

  • 1. Small RNA activation of CDH13 expression overcome BCR-ABL1-independent imatinib-resistance and their signaling pathway studies in chronic myeloid leukemia.
    Su R; Wen Z; Zhan X; Long Y; Wang X; Li C; Su Y; Fei J
    Cell Death Dis; 2024 Aug; 15(8):615. PubMed ID: 39179585
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pristimerin induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation by blocking NF-kappaB signaling and depleting Bcr-Abl.
    Lu Z; Jin Y; Chen C; Li J; Cao Q; Pan J
    Mol Cancer; 2010 May; 9():112. PubMed ID: 20482842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. JKST6, a novel multikinase modulator of the BCR-ABL1/STAT5 signaling pathway that potentiates direct BCR-ABL1 inhibition and overcomes imatinib resistance in chronic myelogenous leukemia.
    Aranda-Tavío H; Recio C; Martín-Acosta P; Guerra-Rodríguez M; Brito-Casillas Y; Blanco R; Junco V; León J; Montero JC; Gandullo-Sánchez L; McNaughton-Smith G; Zapata JM; Pandiella A; Amesty A; Estévez-Braun A; Fernández-Pérez L; Guerra B
    Biomed Pharmacother; 2021 Dec; 144():112330. PubMed ID: 34673425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting Hedgehog signaling pathway and autophagy overcomes drug resistance of BCR-ABL-positive chronic myeloid leukemia.
    Zeng X; Zhao H; Li Y; Fan J; Sun Y; Wang S; Wang Z; Song P; Ju D
    Autophagy; 2015; 11(2):355-72. PubMed ID: 25701353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. System analysis of Huang-Lian-Jie-Du-Tang and their key active ingredients for overcoming CML resistance by suppression of leukemia stem cells.
    Huang G; Yin Z; Wang X; Wen Z; Su R; Li C; Liu Y; Yang J; Hu H; Nie H; Zeng X; Fei J
    Phytomedicine; 2023 Aug; 117():154918. PubMed ID: 37329755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. shRNA library screening identifies nucleocytoplasmic transport as a mediator of BCR-ABL1 kinase-independent resistance.
    Khorashad JS; Eiring AM; Mason CC; Gantz KC; Bowler AD; Redwine HM; Yu F; Kraft IL; Pomicter AD; Reynolds KR; Iovino AJ; Zabriskie MS; Heaton WL; Tantravahi SK; Kauffman M; Shacham S; Chenchik A; Bonneau K; Ullman KS; O'Hare T; Deininger MW
    Blood; 2015 Mar; 125(11):1772-81. PubMed ID: 25573989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overexpression of Tpl2 is linked to imatinib resistance and activation of MEK-ERK and NF-κB pathways in a model of chronic myeloid leukemia.
    Chorzalska A; Ahsan N; Rao RSP; Roder K; Yu X; Morgan J; Tepper A; Hines S; Zhang P; Treaba DO; Zhao TC; Olszewski AJ; Reagan JL; Liang O; Gruppuso PA; Dubielecka PM
    Mol Oncol; 2018 May; 12(5):630-647. PubMed ID: 29485707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cholesterol esterification inhibition and imatinib treatment synergistically inhibit growth of BCR-ABL mutation-independent resistant chronic myelogenous leukemia.
    Bandyopadhyay S; Li J; Traer E; Tyner JW; Zhou A; Oh ST; Cheng JX
    PLoS One; 2017; 12(7):e0179558. PubMed ID: 28719608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ketoconazole Reverses Imatinib Resistance in Human Chronic Myelogenous Leukemia K562 Cells.
    Prado-Carrillo O; Arenas-Ramírez A; Llaguno-Munive M; Jurado R; Pérez-Rojas J; Cervera-Ceballos E; Garcia-Lopez P
    Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BCR-ABL1-independent PI3Kinase activation causing imatinib-resistance.
    Quentmeier H; Eberth S; Romani J; Zaborski M; Drexler HG
    J Hematol Oncol; 2011 Feb; 4():6. PubMed ID: 21299849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Axl Blockade by BGB324 Inhibits BCR-ABL Tyrosine Kinase Inhibitor-Sensitive and -Resistant Chronic Myeloid Leukemia.
    Ben-Batalla I; Erdmann R; Jørgensen H; Mitchell R; Ernst T; von Amsberg G; Schafhausen P; Velthaus JL; Rankin S; Clark RE; Koschmieder S; Schultze A; Mitra S; Vandenberghe P; Brümmendorf TH; Carmeliet P; Hochhaus A; Pantel K; Bokemeyer C; Helgason GV; Holyoake TL; Loges S
    Clin Cancer Res; 2017 May; 23(9):2289-2300. PubMed ID: 27856601
    [No Abstract]   [Full Text] [Related]  

  • 12. S1P Signaling Genes as Prominent Drivers of BCR-ABL1-Independent Imatinib Resistance and Six Herbal Compounds as Potential Drugs for Chronic Myeloid Leukemia.
    Morang S; Bisht M; Upadhyay V; Thapliyal S; Handu S
    OMICS; 2024 Jul; 28(7):367-376. PubMed ID: 38986084
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of a highly potent kinase inhibitor capable of overcoming multiple imatinib-resistant ABL mutants for chronic myeloid leukemia (CML).
    Lu T; Cao J; Zou F; Li X; Wang A; Wang W; Liang H; Liu Q; Hu C; Chen C; Hu Z; Wang W; Li L; Ge J; Shen Y; Ren T; Liu J; Xia R; Liu Q
    Eur J Pharmacol; 2021 Apr; 897():173944. PubMed ID: 33581133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aberrant signalling by protein kinase CK2 in imatinib-resistant chronic myeloid leukaemia cells: biochemical evidence and therapeutic perspectives.
    Borgo C; Cesaro L; Salizzato V; Ruzzene M; Massimino ML; Pinna LA; Donella-Deana A
    Mol Oncol; 2013 Dec; 7(6):1103-15. PubMed ID: 24012109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [MET/ERK and MET/JNK Pathway Activation Is Involved in BCR-ABL Inhibitor-resistance in Chronic Myeloid Leukemia].
    Tsubaki M
    Yakugaku Zasshi; 2018; 138(12):1461-1466. PubMed ID: 30504658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dihydroartemisinin inhibits the Bcr/Abl oncogene at the mRNA level in chronic myeloid leukemia sensitive or resistant to imatinib.
    Lee J; Shen P; Zhang G; Wu X; Zhang X
    Biomed Pharmacother; 2013 Mar; 67(2):157-63. PubMed ID: 23201011
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of imatinib-resistant K562 cell line displaying resistance mechanisms.
    Hekmatshoar Y; Ozkan T; Altinok Gunes B; Bozkurt S; Karadag A; Karabay AZ; Sunguroglu A
    Cell Mol Biol (Noisy-le-grand); 2018 May; 64(6):23-30. PubMed ID: 29808796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gambogic acid induces apoptosis in imatinib-resistant chronic myeloid leukemia cells via inducing proteasome inhibition and caspase-dependent Bcr-Abl downregulation.
    Shi X; Chen X; Li X; Lan X; Zhao C; Liu S; Huang H; Liu N; Liao S; Song W; Zhou P; Wang S; Xu L; Wang X; Dou QP; Liu J
    Clin Cancer Res; 2014 Jan; 20(1):151-63. PubMed ID: 24334603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Platinum pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via DUB inhibition-dependent caspase activation and Bcr-Abl downregulation.
    Lan X; Zhao C; Chen X; Zhang P; Zang D; Wu J; Chen J; Long H; Yang L; Huang H; Wang X; Shi X; Liu J
    Cell Death Dis; 2017 Jul; 8(7):e2913. PubMed ID: 28682311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The antiproliferation effect of berbamine on k562 resistant cells by inhibiting NF-kappaB pathway.
    Wei YL; Liang Y; Xu L; Zhao XY
    Anat Rec (Hoboken); 2009 Jul; 292(7):945-50. PubMed ID: 19548306
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.